CC
Commodore Capital Portfolio holdings
AUM
$1.42B
1-Year Return
73.3%
This Quarter Return
+18.21%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$1.42B
AUM Growth
+$59.6M
(+4.4%)
Cap. Flow
-$29.5M
Cap. Flow
% of AUM
-2.08%
Top 10 Holdings %
Top 10 Hldgs %
62.23%
Holding
38
New
7
Increased
10
Reduced
8
Closed
5
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$59.4M |
| 2 |
Cidara Therapeutics
CDTX
|
$57.2M |
| 3 |
Relay Therapeutics
RLAY
|
$46.2M |
| 4 |
Kymera Therapeutics
KYMR
|
$32.7M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$21.9M |
Top Sells
| 1 |
Vaxcyte
PCVX
|
$62.3M |
| 2 |
Merus
MRUS
|
$49.9M |
| 3 |
Cogent Biosciences
COGT
|
$47.3M |
| 4 |
Soleno Therapeutics
SLNO
|
$45.2M |
| 5 |
Vera Therapeutics
VERA
|
$41.5M |
Sector Composition
| 1 | Healthcare | 99.44% |
| 2 | Financials | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Apogee Therapeutics
APGE
$2.26B
| $12.6M | 0.89% |
290,000
| – | – |
|
27
Inhibikase Therapeutics
IKT
$124M
| $10.5M | 0.74% |
5,397,488
+53,056
| +1% | +$103K |
|
|
PCSC
28
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.97M | 0.56% |
750,000
| – | – |
|
29
Tango Therapeutics
TNGX
$772M
| $7.68M | 0.54% |
+1,500,000
| New | +$7.68M |
|
|
CBIO
30
Crescent Biopharma, Inc. Common Stock
CBIO
$198M
| $7.32M | 0.52% |
+453,686
| New | +$7.32M |
|
31
Neurogene
NGNE
$285M
| $6.4M | 0.45% |
427,866
-497,134
| -54% | -$7.43M |
|
32
VistaGen Therapeutics
VTGN
$109M
| $3.15M | 0.22% |
1,575,000
| – | – |
|
33
Avalo Therapeutics
AVTX
$153M
| $2.41M | 0.17% |
483,000
| – | – |
|
34
Celcuity
CELC
$2.36B
| – | – |
-695,650
| Closed | -$7.03M |
|
35
Cardiff Oncology
CRDF
$144M
| – | – |
-5,384,616
| Closed | -$16.9M |
|
36
Oric Pharmaceuticals
ORIC
$1.06B
| – | – |
-2,000,000
| Closed | -$11.2M |
|
|
37
Vaxcyte
PCVX
$4.29B
| – | – |
-1,650,000
| Closed | -$62.3M |
|
38
Solid Biosciences
SLDB
$428M
| – | – |
-5,825,000
| Closed | -$21.6M |
|